UroGen Pharma Ltd. (URGN) stock
URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$29.79−0.08 (-0.27%)
Close on Nov 18, 2026Market cap $1.46BP/E –Yield –
UroGen Pharma cash
Cash and short-term investments held at the end of each period.
UroGen Pharma's cash was $108.00M at Jun 30, 2026. For fiscal 2025 it was $120.50M, down 50.1% from the year before. Over ten years it grew 21.0% a year on average. The highest annual figure on record is $241.70M in fiscal 2024.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $120.50M | -50.1% |
| FY2024 | Dec 31, 2024 | $241.70M | +70.8% |
| FY2023 | Dec 31, 2023 | $141.50M | +41.6% |
| FY2022 | Dec 31, 2022 | $99.96M | +49.5% |
| FY2021 | Dec 31, 2021 | $66.88M | -34.4% |
| FY2020 | Dec 31, 2020 | $102.02M | -30.6% |
| FY2019 | Dec 31, 2019 | $147.08M | +45.2% |
| FY2018 | Dec 31, 2018 | $101.32M | +38.8% |
| FY2017 | Dec 31, 2017 | $73.00M | +241.7% |
| FY2016 | Dec 31, 2016 | $21.36M | +18.8% |
| FY2015 | Dec 31, 2015 | $17.98M | +364.5% |
| FY2014 | Dec 31, 2014 | $3.87M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $108.00M | -33.2% |
| Q1 FY2026 | Mar 31, 2026 | $140.30M | -30.0% |
| Q4 FY2025 | Dec 31, 2025 | $120.50M | -50.1% |
| Q3 FY2025 | Sep 30, 2025 | $127.40M | -49.9% |
| Q2 FY2025 | Jun 30, 2025 | $161.60M | -33.0% |
| Q1 FY2025 | Mar 31, 2025 | $200.40M | +21.8% |
| Q4 FY2024 | Dec 31, 2024 | $241.70M | +70.8% |
| Q3 FY2024 | Sep 30, 2024 | $254.20M | +65.2% |
| Q2 FY2024 | Jun 30, 2024 | $241.30M | +336.3% |
| Q1 FY2024 | Mar 31, 2024 | $164.50M | +118.8% |
| Q4 FY2023 | Dec 31, 2023 | $141.50M | +41.6% |
| Q3 FY2023 | Sep 30, 2023 | $153.90M | +60.5% |
| Q2 FY2023 | Jun 30, 2023 | $55.30M | -50.8% |
| Q1 FY2023 | Mar 31, 2023 | $75.20M | -45.1% |
| Q4 FY2022 | Dec 31, 2022 | $99.96M | +49.5% |
| Q3 FY2022 | Sep 30, 2022 | $95.90M | -13.1% |
| Q2 FY2022 | Jun 30, 2022 | $112.40M | -7.1% |
| Q1 FY2022 | Mar 31, 2022 | $137.10M | +80.6% |
| Q4 FY2021 | Dec 31, 2021 | $66.88M | -34.4% |
| Q3 FY2021 | Sep 30, 2021 | $110.30M | -7.8% |
| Q2 FY2021 | Jun 30, 2021 | $121.03M | -3.3% |
| Q1 FY2021 | Mar 31, 2021 | $75.91M | -36.3% |
| Q4 FY2020 | Dec 31, 2020 | $102.02M | -30.6% |
| Q3 FY2020 | Sep 30, 2020 | $119.62M | -24.4% |
| Q2 FY2020 | Jun 30, 2020 | $125.12M | -33.9% |
| Q1 FY2020 | Mar 31, 2020 | $119.09M | -51.7% |
| Q4 FY2019 | Dec 31, 2019 | $147.08M | +45.2% |
| Q3 FY2019 | Sep 30, 2019 | $158.19M | +44.5% |
| Q2 FY2019 | Jun 30, 2019 | $189.16M | +58.8% |
| Q1 FY2019 | Mar 31, 2019 | $246.69M | +93.5% |
| Q4 FY2018 | Dec 31, 2018 | $101.32M | +38.8% |
| Q3 FY2018 | Sep 30, 2018 | $109.48M | +38.3% |
| Q2 FY2018 | Jun 30, 2018 | $119.11M | +54.5% |
| Q1 FY2018 | Mar 31, 2018 | $127.46M | +591.7% |
| Q4 FY2017 | Dec 31, 2017 | $73.00M | +241.7% |
| Q3 FY2017 | Sep 30, 2017 | $79.17M | +340.5% |
| Q2 FY2017 | Jun 30, 2017 | $77.09M | – |
| Q1 FY2017 | Mar 31, 2017 | $18.43M | – |
| Q4 FY2016 | Dec 31, 2016 | $21.36M | – |
| Q4 FY2015 | Dec 31, 2015 | $17.98M | – |
See a number that looks wrong?